PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6417752

A method for determining the sampling ratio in epidemiologic studies.

H Morgenstern·D M Winn
View original source ↗Export metadata ↓

Abstract

This paper presents a new method for determining the optimal sampling ratio and sample size in different types of study designs involving binary exposure and disease variables. The sampling ratio is optimized by maximizing cost efficiency, which is the ratio of the precision in effect estimation to the total sampling cost. One may easily compute the optimal sampling ratio with a hand calculator, and it is independent of the sample sizes of the compared groups. Optimal sample sizes obtain from use of the optimal sampling ratio in the appropriate asymptotic power function for comparing two proportions or rates with unequal sample sizes. We illustrate the method with a case-control design, compare it with other methods for optimizing the sampling strategy, and discuss it in a practical context.

Explore related subjects

Cost-Benefit AnalysisHumansSampling StudiesStatistics as TopicComparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Morgenstern, D M Winn. A method for determining the sampling ratio in epidemiologic studies.. https://doi.org/10.1002/sim.4780020311

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial.

In an effort to determine the total one-year cost of liver transplantation, the underlying drivers of that cost, and any cost differences between alternative immunosuppressive regimens, an analysis was performed comparing the average one-year posttransplant charges of 322 patients participating in the "U.S. Multi-center Prospective Randomized Trial Comparing FK-506 to Cyclosporine in Liver Transplantation." Total one-year inpatient charges including all readmissions were examined. Professional fees and outpatient charges were excluded. Costs for tacrolimus drug and blood assays were assumed to be equal to those in the CsA group. For patients completing the study, the tacrolimus group had an average length of stay and average one-year cost seven days (P = .06) and $19,290 (P = .05) lower than the CsA group. The difference in rejection profiles between the two arms seems to largely account for the lower costs. The tacrolimus arm consistently had fewer patients in the more severe rejection groups. Increased incidence and severity of rejection were directly related to higher average lengths of stay and costs of transplantation (P < .001). Tacrolimus immunosuppression during the first year after liver transplantation is more cost-effective than CsA in achieving similar patient and graft survival rates. Differing incidence and severity of rejection can dramatically affect the first-year cost of liver transplantation.

Cost-Benefit Analysis↗